These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 9436478

  • 1. [Treatment of familial combined hyperlipidemia].
    Bruckert E.
    Ann Endocrinol (Paris); 1997; 58(4):297-301. PubMed ID: 9436478
    [No Abstract] [Full Text] [Related]

  • 2. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia.
    Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, Didangelos TP, Carina MV, Kranitsas DF, Kontopoulos AG.
    Am J Cardiol; 1997 Sep 01; 80(5):608-13. PubMed ID: 9294990
    [Abstract] [Full Text] [Related]

  • 3. Atorvastatin versus four statin-fibrate combinations in patients with familial combined hyperlipidaemia.
    Athyros VG, Papageorgiou AA, Athyrou VV, Demitriadis DS, Pehlivanidis AN, Kontopoulos AG.
    J Cardiovasc Risk; 2002 Feb 01; 9(1):33-9. PubMed ID: 11984215
    [Abstract] [Full Text] [Related]

  • 4. Statin-fibrate combinations in patients with combined hyperlipedemia.
    Athyros VG, Papageorgiou AA, Kontopoulos AG.
    Atherosclerosis; 2001 Mar 01; 155(1):263-4. PubMed ID: 11293392
    [No Abstract] [Full Text] [Related]

  • 5. The effects of fibrates on lipoprotein and hemostatic coronary risk factors.
    Schonfeld G.
    Atherosclerosis; 1994 Dec 01; 111(2):161-74. PubMed ID: 7718018
    [Abstract] [Full Text] [Related]

  • 6. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
    Mikhailidis DP, Jagroon IA.
    Metabolism; 2001 Nov 01; 50(11):1385-6. PubMed ID: 11715936
    [No Abstract] [Full Text] [Related]

  • 7. Drug interactions with fibric acids.
    Lozada A, Dujovne CA.
    Pharmacol Ther; 1994 Aug 01; 63(2):163-76. PubMed ID: 7809177
    [Abstract] [Full Text] [Related]

  • 8. Implication of fibrate therapy for homocysteine.
    Goffin E, Jamar F, Desager JP, Devuyst O.
    Lancet; 1999 Oct 02; 354(9185):1209. PubMed ID: 10513738
    [No Abstract] [Full Text] [Related]

  • 9. Drug treatment of combined hyperlipidemia.
    Wierzbicki AS, Mikhailidis DP, Wray R.
    Am J Cardiovasc Drugs; 2001 Oct 02; 1(5):327-36. PubMed ID: 14728015
    [Abstract] [Full Text] [Related]

  • 10. Lipid profiles on fibric-acid derivatives.
    Capps NE.
    Lancet; 1994 Sep 03; 344(8923):684-5. PubMed ID: 7915370
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Ciprofibrate and lipid profile.
    Chandler HA, Batchelor AJ.
    Lancet; 1994 Jul 09; 344(8915):128-9. PubMed ID: 7912363
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Long-term treatment of hyperlipoproteinemia with etofibrate].
    Bartz VT, Gatz J, Slotty C, Schröter C, Töle R, Wand P.
    Fortschr Med; 1993 Sep 10; 111(25):398-400. PubMed ID: 8406286
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Paradoxical high-density lipoprotein reduction induced by fenofibrate and ciprofibrate.
    Collinson PO, Hjelm CJ, Canepo-Anson R.
    Ann Clin Biochem; 1996 Mar 10; 33 ( Pt 2)():159-61. PubMed ID: 8729728
    [No Abstract] [Full Text] [Related]

  • 19. [Cytolytic hepatic damage caused by ciprofibrate].
    Perault MC, Fievre JL, Dejean C, Martin A, Vandel B.
    Gastroenterol Clin Biol; 1992 Mar 10; 16(6-7):609. PubMed ID: 1526424
    [No Abstract] [Full Text] [Related]

  • 20. Drugs recently released in Belgium. Mefloquine--ciprofibrate.
    Harvengt C.
    Acta Clin Belg; 1991 Mar 10; 46(2):117-9. PubMed ID: 1649529
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.